Clinical Trial Update: Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating dupilumab for Allergic Fungal Rhinosinusitis after endoscopic sinus surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Fungal Rhinosinusitis
• Asthma
• Nasal Polyps
• Rhinosinusitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD) | Conditions: Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS) | Phase 3 | Status: WITHDRAWN